Health and Fitness Health and Fitness
Wed, October 31, 2012
Tue, October 30, 2012
Mon, October 29, 2012
Sun, October 28, 2012
Fri, October 26, 2012
Thu, October 25, 2012
Wed, October 24, 2012
Tue, October 23, 2012
Mon, October 22, 2012
Sun, October 21, 2012
Sat, October 20, 2012
Fri, October 19, 2012
Thu, October 18, 2012
Wed, October 17, 2012
Tue, October 16, 2012
Mon, October 15, 2012
Sun, October 14, 2012
Fri, October 12, 2012
Thu, October 11, 2012
Wed, October 10, 2012
Tue, October 9, 2012
Mon, October 8, 2012
Sun, October 7, 2012
Sat, October 6, 2012
Fri, October 5, 2012
Thu, October 4, 2012

Uroplasty To Issue Second Quarter Of Fiscal 2013 Financial Results On October 25, 2012


//health-fitness.news-articles.net/content/2012/ .. l-2013-financial-results-on-october-25-2012.html
Published in Health and Fitness on Wednesday, October 17th 2012 at 4:47 GMT by Market Wire   Print publication without navigation


Uroplasty To Issue Second Quarter Of Fiscal 2013 Financial Results On October 25,... -- MINNEAPOLIS, Oct. 17, 2012 /PRNewswire/ --

MINNEAPOLIS, Oct. 17, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]) announced today that it will release financial results for the second quarter of fiscal 2013 ended September 30, 2012 at the market close on Thursday, October 25, 2012. The Company will host a conference call to discuss these results on Thursday, October 25, 2012 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen , President and Chief Executive Officer, and Medi Jiwani , Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-0843. An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4568214#.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians.  Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at [ www.uroplasty.com ].

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140

 

EVC Group

Doug Sherk (Investors), 415.652.9100

Jenifer Kirtland (Investors), 415.568.9349

Chris Gale (Media), 646.201.5431

SOURCE Uroplasty, Inc.




Publication Contributing Sources